**Core tip:** A total of 120 patients with chronic ulcerative colitis were included in this study to examine the efficacy and safety of stellate ganglion block in patients with chronic ulcerative colitis. The results revealed that stellate ganglion block effectively improves the efficacy of chronic ulcerative colitis treatment, relieves clinical symptoms in patients, and reduces the level of inflammatory factors. Furthermore, this technique has fewer adverse reactions, making it safe and reliable.

INTRODUCTION
============

Chronic ulcerative colitis is a common disease and has a high incidence. Its main clinical manifestations include abdominal pain, tenesmus and sepsis, and it can decrease the quality of life of patients\[[@B1]-[@B6]\]. Ulcers of the colonic mucosa occur in patients with this disease, which can affect the entire colon and rectum, and can easily induce repeated attacks. Sulfasalazine is a commonly used conventional treatment for chronic ulcerative colitis. However, this treatment has certain limitations such as frequent recurrence and side effects. Hence, there is a need for better treatment options\[[@B7]-[@B13]\]. Although the pathogenesis of chronic ulcerative colitis is unclear, a close relationship between the disease and immune dysfunction has been confirmed. Furthermore, the expression of cytokines, particularly interleukin-8 (IL-8), significantly increases during the disease course\[[@B14]-[@B22]\]. Stellate ganglion block is a very common clinical block technique that has been used since the beginning of the last century. Studies have shown that stellate ganglion blocks can regulate multiple system functions in the body, and has a good effect on blood pressure, hyperthyroidism, peripheral facial paralysis and other diseases\[[@B23]-[@B27]\]. With the current rapid development of medicine, some scientists have found that the stellate ganglion block technique also plays an important role in regulating the immune system\[[@B28]-[@B32]\]. Thus, we speculate that stellate ganglion blocks may also have a role in the treatment of chronic ulcerative colitis. Therefore, the main purpose of this study was to examine the efficacy and safety of stellate ganglion block treatment in patients with chronic ulcerative colitis.

MATERIALS AND METHODS
=====================

General information
-------------------

A total of 120 randomly selected patients with chronic ulcerative colitis treated in Cangzhou Central Hospital between January 2014 and January 2016 were included in this study. These patients were divided into two groups: control group (*n* = 30) and experimental group (*n* = 90). The control group comprised 19 male patients (63.3%) and 11 female patients (36.7%) aged between 39 and 56 years, with a mean age of 47.1 ± 5.9 years. Furthermore, the disease course ranged from two months to 10 years, with an average of 4.1 ± 1.4 years. The experimental group comprised 54 male patients (60.0%) and 36 female patients (40.0%), aged between 40 and 57 years, with a mean age of 48.2 ± 6.0 years. Furthermore, the disease course ranged from four months to nine years, with an average of 4.3 ± 1.5 years. Patients in the experimental group were not allergic to lidocaine and had no coagulation disorders. This study was approved by the ethics committee of the institution.

Methods
-------

In the control group, patients received four doses of sulfasalazine twice a day orally. In the experimental group, patients received stellate ganglion block treatment once a day for 30 d. The blocking method used was as follows: 10 mL of 1% lidocaine was injected into the sixth cervical vertebrae, and Horner syndrome was observed in these patients. The stellate ganglion block technique was considered successful when no abnormal situations occurred within 30 min.

Outcome measures
----------------

**Clinical symptoms and IL-8 level:** Clinical symptoms were observed before and after treatment. Blood was drawn from patients at the beginning of treatment, on the morning of day 0, and on the 10^th^, 20^th^ and 30^th^ day after treatment. IL-8 levels were then determined by enzyme-linked immunosorbent assay. Changes in clinical symptoms and related indicators were analyzed and compared in the two groups after treatment.

**Screening colonoscopy:** Colonoscopy lesions were scored before and after treatment using the Rachmilewitz scoring system.

Statistical analysis
--------------------

SPSS 17.0 software was used for statistical analysis. Time to defecation and cytokine expression level were determined. The two treatment groups were compared using the *t*-test. The number of cases of abdominal pain, pus and tenesmus were used as enumeration data. Comparisons in these two groups were evaluated using Pearson\'s *χ*^2^ test.

RESULTS
=======

Comparison of related indices in the two groups before treatment
----------------------------------------------------------------

The differences in the number of patients with blood and pus and tenesmus accompanied by abdominal pain and the average time to defecation before treatment in the control and experimental groups were not statistically significant (*P* \> 0.05). In addition, the difference in IL-8 expression level between these two groups were not statistically significant (*P* \> 0.05), as shown in Table [1](#T1){ref-type="table"}.

###### 

Clinical symptoms in the control and experimental groups before treatment *n* (%)

  **Indices (clinical symptoms)**   **Control group (*n* = 30)**   **Experimental group (*n* = 90)**   **t/*χ^2^***   ***P* value**
  --------------------------------- ------------------------------ ----------------------------------- -------------- ---------------
  Stomach ache                      17 (56.67)                     50 (55.56)                          0.025          0.874
  Time to defecation (^-^x ± s)     8.50 ± 1.31                    8.71 ± 1.40                         -0.723         0.471
  Blood and pus                     10 (33.33)                     29 (32.22)                          0.028          0.867
  Tenesmus                          13 (43.33)                     38 (42.22)                          0.025          0.874
  Interleukin-8 (ng/L)              25.83 ± 3.01                   24.97 ± 2.98                        1.366          0.175

Remission of clinical symptoms in the two groups after treatment
----------------------------------------------------------------

Clinical symptoms in patients in the control and experimental groups were alleviated after treatment. However, abdominal pain was not significantly relieved in patients in the control group. Furthermore, remission in the experimental group was better than that in the control group, and the difference was statistically significant (*P* \< 0.05; Table [2](#T2){ref-type="table"}).

###### 

Clinical symptoms of patients in the two groups after treatment *n* (%)

  **Group**            **Stomach ache**                           **Time to defecation (^-^x ± s )**            **Blood and pus**                          **Tenesmus**
  -------------------- ------------------------------------------ --------------------------------------------- ------------------------------------------ ------------------------------------------
  Control group                                                                                                                                            
  Before treatment     17 (56.67)                                 8.50 ± 1.31                                   10 (33.33)                                 13 (43.33)
  After treatment      13 (43.33)                                 2.91 ± 0.97                                   5 (16.67)                                  7 (23.33)
  t/*χ^2^*             3.548                                      18.784                                        7.401                                      9.000
  *P* value            0.060                                      0.000                                         0.007                                      0.003
  Experimental group                                                                                                                                       
  Before treatment     50 (55.56)                                 8.71 ± 1.40                                   29 (32.22)                                 38 (42.22)
  After treatment      8 (8.89)[a](#T2FN1){ref-type="table-fn"}   1.12 ± 0.87[a](#T2FN1){ref-type="table-fn"}   4 (4.44)[a](#T2FN1){ref-type="table-fn"}   6 (6.67)[a](#T2FN1){ref-type="table-fn"}
  t/*χ^2^*             49.864                                     43.684                                        25.776                                     34.213
  *P* value            0.000                                      0.000                                         0.000                                      0.000

*P* \< 0.05 *v*s the control group.

Comparison of IL-8 expression levels in patients after treatment
----------------------------------------------------------------

In this study, IL-8 expression level was significantly lower in the experimental group than in the control group; and the difference was statistically significant (*P* \< 0.05). Furthermore, the duration of treatment and IL-8 expression were significantly reduced in the experimental group, and the differences were statistically significant (*P* \< 0.05). However, these differences were not significant in the control group. The maximum value of the measured data was reached at day 0 in the control group, while the minimum value was reached during the first 30 d in the experimental group. In addition, no interactions (*F* = 2.981, *P* = 0.139) between the different time points and groupings were observed (Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).
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###### 

Comparison of interleukin-8 expression levels between the control and experimental groups

  **Group**            **Different time points**   **Mean**       **F**          ***P* value**                                                                             
  -------------------- --------------------------- -------------- -------------- --------------- -------------- ---------------------------------------------------------- ----------------------------------------------------------
  Control group        25.83 ± 3.01                25.23 ± 2.87   24.68 ± 2.99   24.34 ± 2.98    25.02 ± 2.95   2.191                                                      0.060
  Experimental group   24.97 ± 2.98                22.20 ± 2.90   15.95 ± 2.62   8.81 ± 2.13     17.98 ± 2.54   9.715                                                      0.000
  Mean                 25.40 ± 2.95                23.72 ± 2.88   20.32 ± 2.71   16.58 ± 2.35    19.26 ± 2.52   6.114                                                      0.008
  *t*                  1.366                       4.969          15.249         31.117          12.617         (F = 5.491, *P* = 0.032)[1](#T3FN1){ref-type="table-fn"}   (F = 2.981, *P* = 0.139)[2](#T3FN2){ref-type="table-fn"}
  *P* value            0.175                       0.000          0.000          0.000           0.000                                                                     

Overall comparison of F statistics and *P* values between the control and experimental groups;

Interactions between F statistics and *P* values.

Colonoscopy scores in the two groups before and after treatment
---------------------------------------------------------------

Colonoscopy scores significantly decreased at 30 d after treatment in both groups. However, these scores decreased more significantly in the experimental group, compared with the control group; and the difference was statistically significant (*P* \< 0.05; Figure [2](#F2){ref-type="fig"}).
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Adverse reactions
-----------------

In the control group, 13 patients experienced stomach discomfort, liver and kidney dysfunction, headache, and other adverse reactions. In the experimental group, only seven patients had mild pain in the neck, which disappeared after a few days. The proportion of adverse events was significantly higher in the control group; and the difference was statistically significant (*χ^2^* = 33.215, *P* = 0.000; Table [4](#T4){ref-type="table"}).

###### 

Adverse reactions in the control and experimental groups after treatment

  **Group**            **Stomach discomfort**   **Liver and kidney dysfunction**   **Headache**   **Rashes**   **Vomiting**   **Neck pain**   **Incidence**
  -------------------- ------------------------ ---------------------------------- -------------- ------------ -------------- --------------- ---------------
  Control group        5                        1                                  3              2            2              0               43.33%
  Experimental group   0                        0                                  0              0            0              7               7.78%

DISCUSSION
==========

In recent years, the incidence of chronic ulcerative colitis has gradually increased. This recurrent disease causes serious harm to human health\[[@B33]-[@B36]\]. Sulfasalazine is a commonly used drug for treating chronic ulcerative colitis. However, due to its side effects, better methods of treatment are required\[[@B37]-[@B40]\]. The pathogenesis of chronic ulcerative colitis is complex. However, recent studies have shown that this disease and immune dysfunction are correlated\[[@B41],[@B42]\], and that the stellate ganglion block technique plays a very important role in regulating immune function\[[@B43]-[@B46]\]. Therefore, the main aim of this study was to investigate the efficacy and safety of the stellate ganglion block technique in the treatment of chronic ulcerative colitis.

IL-8 content in patients in the two groups before and after treatment
---------------------------------------------------------------------

Research has shown that the occurrence of chronic ulcerative colitis is accompanied by the formation of immune complexes and cytokines, which is difficult to treat\[[@B47]\]. Of these cytokines, IL-8 can lead to chemotaxis of neutrophils, eosinophils, lymphocytes and other cells, and the release of media that can damage endothelial cells and related tissues and organs, leading to inflammation\[[@B48]\]. In this study, stellate ganglion block was administered 30 times to patients in the experimental group and led to a reduction in IL-8 expression. The level of IL-8 expression did not significantly change in patients in the control group. In addition, abdominal pain was not significantly relieved after treatment in the control group, while abdominal pain was relieved in the experimental group. This suggests that neutrophil chemotactic factors are released through the activation of macrophages in patients with chronic ulcerative colitis, and both macrophages and neutrophils can increase IL-8 secretion, leading to inflammation\[[@B47]\]. After stellate ganglion block treatment, the inflammatory chemokine IL-8 was reduced in patients in the experimental group, chemotaxis was inhibited, and peripheral blood histamine only slightly increased; thus, reducing inflammation\[[@B48]\].

Changes in clinical symptoms in the two groups before and after treatment
-------------------------------------------------------------------------

Abdominal pain, tenesmus and sepsis are the main clinical manifestations of chronic ulcerative colitis, which seriously affect the normal daily life of patients\[[@B6]\]. Sulfasalazine is a commonly used drug for treating chronic ulcerative colitis. However, it has some limitations due to its side effects\[[@B10]\]. Therefore, this study used stellate ganglion block as a new method for treating this disease from the perspective of immunology. Patients were divided in the control group who were treated with conventional sulfasalazine, and the experimental group in which patients were treated with stellate ganglion block.

Pus and tenesmus symptoms were significantly reduced in both groups. The time to defecation was also significantly reduced in both groups, but relief of clinical symptoms was more obvious in the experimental group. Furthermore, colonoscopy scores were significantly decreased in the experimental group compared with the control group. In addition, research has shown that immune function in the human body induces environment stability and defense, as well as other vital functions; and counting and activity improves humoral immunity. Finally, this treatment reduces the production of inflammatory cytokines *in vivo* in patients with chronic ulcerative colitis, and improves clinical symptoms\[[@B49]\]. Furthermore, studies have shown that the stellate ganglion block technique improves blood circulation by inhibiting the activity of the sympathetic nervous system. This can provide chronic ulcerative colitis patients with immune complexes and induces the rapid clearance of inflammatory cytokines, thereby improving the condition of patients\[[@B50]\].

Adverse reactions
-----------------

Fewer adverse symptoms were observed following treatment with the stellate ganglion block technique, and the liver, kidney, stomach and other organs were less affected, when compared with the control group. These findings indicate that the stellate ganglion block has good healing power and few side effects, demonstrating that this treatment is safe and reliable.

This study has limitations. The sample size was small. Furthermore, IL-8 levels in patients included into this study were not compared with healthy subjects. Hence, further studies with a larger sample size are needed.

In conclusion, the stellate ganglion block technique is a new method for treating chronic ulcerative colitis. This method can significantly improve clinical symptoms, reduce the production of inflammatory cytokines, has fewer adverse reactions, and is safe and reliable, thereby improving the quality of life of patients. This technique is worthy of further research conducted with a larger sample size, and could be used in clinical practice.

COMMENTS
========

Background
----------

Chronic ulcerative colitis is common, and has a high incidence. Abdominal pain, tenesmus and sepsis are the main clinical manifestations of this disease, which can decrease the quality of life of patients. Ulcers of the colonic mucosa occur in patients with chronic ulcerative colitis, which can affect the entire colon and rectum, and induce repeated attacks. Sulfasalazine is a commonly used conventional treatment for chronic ulcerative colitis. However, it has certain limitations such as disease recurrence and side effects. Hence, there is a need for better treatment options.

Research frontiers
------------------

Although the pathogenesis of chronic ulcerative colitis is unclear, the close relationship between this disease and immune dysfunction has been confirmed. Furthermore, the expression levels of cytokines, particularly interleukin-8, significantly increases during the disease course.

Innovations and breakthroughs
-----------------------------

Stellate ganglion block is a very common clinical block technique that has been used since the beginning of the last century. Studies have shown that stellate ganglion block can regulate multiple system functions in the body, and has a good effect on blood pressure, hyperthyroidism, peripheral facial paralysis and other diseases. With the current rapid development of medicine, some scientists have found that the stellate ganglion block technique also plays an important role in regulating the immune system. Thus, we speculate that stellate ganglion blocks may also have a role in the treatment of chronic ulcerative colitis.

Applications
------------

The stellate ganglion block technique can effectively improve the efficacy of chronic ulcerative colitis treatment, relieve clinical symptoms in patients, and reduce the level of inflammatory factors. Furthermore, it has fewer adverse reactions, thereby making it a safe and reliable treatment method.

Peer-review
-----------

Stellate ganglion block technique can effective improve the efficiency of chronic ulcerative colitis treatment, relieve the clinical symptoms of patients, and reduce the level of inflammatory factors. Furthermore, it has fewer adverse reactions, thereby allowing it to be a safe and reliable treatment method. This technique is worthy of further studies conducted with large sample sizes, and can be used in clinical practice.
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